Cocrystal Pharma Inc SEC Filings

Cocrystal Pharma (COCP) insider Phillip Frost reported an equity transaction involving 20,000 shares of common stock at a weighted average price of $0.9406 per share on 11/25/2025. The filing shows these shares as indirectly owned through Frost Gamma Investments Trust, bringing his indirect beneficial ownership via that trust to 1,699,551 shares after the transaction. He also reports direct beneficial ownership of 27,100 shares of common stock, which includes shares issuable upon vesting of restricted stock units. Frost is identified as both a director and a 10% owner of Cocrystal Pharma, and the filing clarifies that he disclaims beneficial ownership of certain shares except to the extent of any pecuniary interest.

Cocrystal Pharma (COCP) reported Q3 2025 results showing a net loss of $2.049 million and operating expenses of $2.089 million, reflecting sharp year‑over‑year cost reductions. For the nine months, net loss was $6.405 million as R&D spending eased following completion of a Phase 2a influenza study and Phase 1 norovirus/coronavirus trial work.

Liquidity remains tight. Cash and restricted cash were $7.804 million as of September 30, 2025, after using $6.456 million in operating cash year‑to‑date. Management stated there is “substantial doubt” about continuing as a going concern. To bolster funds, the company raised net $4.183 million in a September 12, 2025 registered direct offering (with concurrent private warrants) and $154,000 via ATM sales. Subsequent to quarter end, insiders purchased 739,426 units for gross proceeds of $1.03 million on October 28, 2025.

Pipeline updates: Oral CC‑42344 for influenza A completed Phase 2a with favorable safety. CDI‑988 completed Phase 1 with tolerability across doses up to 1,200 mg; the FDA cleared a Phase 1b norovirus challenge study, expected to begin in the first half of 2026. The company also reported a $500,000 NIH/NIAID SBIR Phase I award.

Cocrystal Pharma (COCP)10/28/2025. He acquired 359,713 shares of common stock at $1.39 per unit, with each unit also including a warrant to purchase two shares. He also acquired 719,426 warrants with a $1.24 exercise price, which were exercisable upon issuance and expire on 01/28/2028. The transaction was approved by a Special Committee under Rule 16b-3.

Following these transactions, Frost beneficially owned 1,679,551 shares indirectly through Frost Gamma Investments Trust, and 27,100 shares directly, which include shares issuable upon vesting of restricted stock units.

Cocrystal Pharma (COCP): director-affiliated entity reports purchase

Caret Group, LLC, a director of Cocrystal Pharma, reported buying 359,713 shares at $1.39 per unit on 10/28/2025. Each unit included one share and a warrant to purchase two shares. The filing shows 719,426 warrants acquired with a $1.24 exercise price, exercisable upon issuance and expiring on 01/28/2028.

Following the transaction, the reporting person beneficially owned 1,383,009 shares. This total includes shares issuable upon vesting of restricted stock units, as noted in the filing’s footnote.

Cocrystal Pharma (COCP) director Richard Pfenniger reported a purchase on 10/28/2025. He acquired 20,000 shares of common stock as part of units priced at $1.39 per unit, with each unit consisting of one share and a warrant to buy two shares. He also acquired 40,000 warrants with an exercise price of $1.24 and an expiration of 01/28/2028; the warrants were exercisable upon issuance.

Following the transactions, he beneficially owned 31,400 shares directly, which includes shares issuable upon vesting of restricted stock units. The purchase was approved by a Special Committee of the Board under Rule 16b-3.

Cocrystal Pharma (COCP) reported an insider purchase by a senior officer. On 10/28/2025, the reporting person acquired 3,598 shares of common stock at $1.39 per unit, with each unit also including warrants to buy two shares. The filing also shows acquisition of 7,196 warrants with a $1.24 exercise price, exercisable upon issuance and expiring on 01/28/2028. Following the transactions, beneficial ownership stands at 44,167 shares held directly, which includes shares issuable upon vesting of restricted stock units.

Cocrystal Pharma entered a private placement with four accredited insiders, selling 739,426 units at $1.39 per unit. Each unit includes one common share and a warrant to buy two shares at $1.24 per share for 27 months. The transaction generated $1.03 million in gross proceeds.

The sale was conducted at-the-market under Nasdaq rules and carried no registration rights. The offering relied on Section 4(a)(2) and Rule 506(b) exemptions. If fully exercised, the warrants would be exercisable for 1,478,852 additional shares.

Cocrystal Pharma (COCP) filed an 8-K stating it announced receipt of a Small Business Innovation Research (SBIR) Phase I award from the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID). The announcement was made on October 27, 2025.

The company furnished a press release as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). The company states this information is furnished and not deemed “filed” under Section 18 of the Exchange Act, and it is not incorporated by reference into other filings. Cocrystal’s common stock trades on the Nasdaq Capital Market under the symbol COCP.